About Solarea Bio
Solarea Bio is a company based in Cambridge (United States) founded in 2017 by Gerardo V Toledo. Solarea Bio has raised $37.24 million across 5 funding rounds from investors including Illumina, GISEV and S2G Ventures. Solarea Bio offers products and services including SBD111, SBD121, SBD3, SBD4, and Bondia. Solarea Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Cambridge, United States
- Founders Gerardo V Toledo
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Solarea Bio, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$37.24 M (USD)
in 5 rounds
-
Latest Funding Round
$9.91 M (USD), Series A
Nov 04, 2025
-
Investors
Illumina
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Solarea Bio
Solarea Bio offers a comprehensive portfolio of products and services, including SBD111, SBD121, SBD3, SBD4, and Bondia.
Clinically validated to slow bone loss in humans.
Developed for dietary needs in rheumatoid arthritis patients.
Targets dietary requirements for psoriatic arthritis management.
Addresses cellular aging through microbial innovations.
Beta launch for microbial solutions in health applications.
People of Solarea Bio
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Solarea Bio
Solarea Bio has successfully raised a total of $37.24M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $9.91 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Solarea Bio
Solarea Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina, GISEV and S2G Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage agnostic venture capital firm
|
Locked | Locked | Locked | |
|
Early-stage life sciences and tech focused VC firm investing primarily in the US
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Solarea Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Solarea Bio
Investment portfolio details for Solarea Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Solarea Bio
Detailed financials for Solarea Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Solarea Bio Comparisons
Peer comparison for Solarea Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Solarea Bio
Solarea Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Solarea Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solarea Bio
Complete news archive for Solarea Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Solarea Bio
Solarea Bio was founded in 2017.
Solarea Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Gerardo V Toledo is the current CEO of Solarea Bio. They have also founded this company.
Solarea Bio is a funded company, having raised a total of $37.24M across 5 funding rounds to date.
Solarea Bio was founded in 2017 and is based in Cambridge, United States. Therapeutics based on the microbiome are developed, with probiotics sourced from natural origins. Services encompassing microbial genomics, metagenomics, and genome-wide metabolic models are provided to validate potential candidates. Operations are centered in the biotechnology sector, targeting health-related applications through microbial research.
Solarea Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Solarea Bio offers SBD111, SBD121, SBD3, SBD4, and Bondia.
Solarea Bio has 6 investors. Key investors include Illumina, GISEV, S2G Ventures, Bold Capital Partners, and Viking Global Investors.